Acute myocardial infarction is a severe ischemic disease responsible for heart failure and sudden death. Here, we show that after acute myocardial infarction in mice, mature B lymphocytes selectively produce Ccl7 and induce Ly6C hi monocyte mobilization and recruitment to the heart, leading to enhanced tissue injury and deterioration of myocardial function. Genetic (Baff receptor deficiency) or antibody-mediated (CD20-or Baff-specific antibody) depletion of mature B lymphocytes impeded Ccl7 production and monocyte mobilization, limited myocardial injury and improved heart function. These effects were recapitulated in mice with B cell-selective Ccl7 deficiency. We also show that high circulating concentrations of CCL7 and BAFF in patients with acute myocardial infarction predict increased risk of death or recurrent myocardial infarction. This work identifies a crucial interaction between mature B lymphocytes and monocytes after acute myocardial ischemia and identifies new therapeutic targets for acute myocardial infarction. 
Acute thrombotic obstruction of the blood flow in coronary arteries precipitates myocardial infarction, with deleterious consequences on heart function [1] [2] [3] [4] . The mainstay of treatment involves rapid restoration of a patent coronary artery either mechanically or through thrombolytic and antiplatelet therapies and administration of agents that reduce oxygen consumption and protect the heart muscle 1, 5 . Still, the clinical and socio-economic burden of ischemic heart disease is unacceptably high, and the efficacy of multiantithrombotic therapies is often mitigated by an increased risk of hemorrhagic events. Thus, efforts are being directed toward targeting other pathophysiological pathways, particularly those involved in postischemic cardiac remodeling 4, 6 .
The immune system becomes activated in response to myocardial damage 7 . Shortly after ischemia, the damaged tissue exposes ligands (for example, non-myosin heavy chain type IIA and C) that are recognized by components of the innate immune system, which leads to its activation [8] [9] [10] [11] [12] . C-reactive protein, a short pentraxin acute-phase protein, also binds damaged tissue and activates complement, leading to aggravation of tissue injury in the setting of acute myocardial infarction 13 . In contrast, long pentraxin 3, a molecule that limits complement activation, has a cardioprotective role in this setting 14 . The acute inflammatory response also leads to the mobilization and recruitment of innate immune cells. A few hours after the ischemic insult, neutrophils are actively recruited into the ischemic tissue and contribute to tissue inflammation and cardiovascular injury through the production of inflammatory mediators, reactive oxygen species and various proteases 15, 16 . This wave of neutrophil infiltration is followed by the mobilization and recruitment of monocytes. Recent studies have shed light on the mechanisms by which monocytes are recruited to the heart and the life cycle of the recruited monocytes in the setting of acute myocardial infarction. These studies have suggested that Ly6C hi and Ly6C lo monocytes have pathogenic and protective roles, respectively, in cardiac remodeling and preservation of heart function 17, 18 .
Whether targeting the immune response in acute myocardial infarction would be beneficial is still uncertain. Attempts to target the complement pathway have not been efficacious in patients with acute myocardial infarction [19] [20] [21] [22] . Better characterization of the immune response following ischemic injury and the mechanisms by which it contributes to tissue damage is therefore required to fill the existing gap of knowledge that limits clinical translation.
Here, we addressed the role of mature B lymphocytes, a subset of immune cells that orchestrates a variety of adaptive immune responses relevant to human diseases 23 but that has relatively been neglected in RESULTS Mature B cells are recruited to the ischemic myocardium To identify the inflammatory cell repertoire within the injured myocardium, we induced acute myocardial infarction in C57BL/6J mice by permanent coronary artery ligation and analyzed cell suspensions of digested infarcts at different time points by flow cytometry. We found that neutrophil counts (CD11b + Ly6G hi 7/4 hi cells; 7/4 refers to antibody clone 7/4 directed against the Ly-6B.2 alloantigen, whose staining is equivalent to staining with Ly6C) peaked at day 1 after myocardial infarction (Supplementary Fig. 1a) , followed by successive waves of 7/4 hi (Ly6C hi ) and 7/4 lo (Ly6C lo ) monocytes (CD11b hi Ly6G − ) (Supplementary Fig. 1b ) and by accumulation of dendritic cells, macrophages and natural killer cells ( Supplementary  Fig. 1c,d ). We also found that CD3 + T lymphocytes accumulated in the injured myocardium within 1 d after myocardial infarction and their numbers dropped thereafter (Supplementary Fig. 1e ). These results are in agreement with previous studies 17 .
We next characterized B lymphocyte infiltration into the ischemic cardiac tissue. After myocardial infarction, B lymphocytes, defined as B220 + IgM + cells, accumulated in the infarct area, with a peak in their numbers on day 5 after infarction. Their numbers waned thereafter to levels comparable to those in sham-operated mice ( Supplementary  Fig. 2a ). Immunohistological and additional flow cytometry analyses confirmed the increased numbers of both B220 + and CD19 + IgD + IgM low B lymphocytes in the border infarct area compared to their numbers in cardiac tissue from sham-operated mice (Supplementary Fig. 2b,c) . Thus, myocardial infarction triggers the infiltration of circulating mature B lymphocytes into cardiac tissue, suggesting a potential role of B cell-mediated immune response in this setting.
B cell depletion improves cardiac function
To directly assess the role of mature B lymphocytes in cardiac remodeling after myocardial infarction, we depleted B lymphocytes using a CD20-specific monoclonal antibody (CD20 mAb) 24, 25 . As expected, we found that CD20 mAb treatment led to a sustained and profound reduction of the number of mature B lymphocytes in cardiac tissue (Supplementary Fig. 3a) , peripheral blood (Fig. 1a) and spleen ( Supplementary Fig. 3b ). Both follicular and marginal zone B cells were depleted (Supplementary Fig. 3c , whereas B1 cells were preserved during the duration of the experiment (data not shown) 26 .
We next assessed cardiac function by echocardiography 14 d after myocardial infarction. CD20 mAb-induced B cell depletion led to a smaller end-systolic left ventricular dimension (P = 0.016), a significant improvement of left ventricular fractional shortening (P = 0.021) and increased left ventricular myocardial contractility (P = 0.025) compared to PBS-treated control mice (Fig. 1b) . This treatment also led to a smaller infarct size (P = 0.024) and less interstitial fibrosis as assessed by collagen content (P = 0.016) (Fig. 1c) . In addition, B cell depletion reduced the number of apoptotic cells within the injured myocardium, as shown by TUNEL staining (P = 0.005), but had no effect on neovascularization ( Supplementary Fig. 4) . Overall, these results show that systemic B cell depletion significantly reduces post-ischemic injury, prevents adverse ventricular remodeling and improves cardiac function after acute myocardial infarction. B cell depletion reduces proinflammatory responses Previous studies reported a pathogenic role for natural IgM antibodies in the first 24 h after ischemia-reperfusion injury 11, 27 . To address potential mechanisms involved in B cell-mediated effects on cardiac remodeling and function, we assessed changes in antibody production after CD20 mAb treatment. Depletion of mature B cells did not alter IgM or IgG abundance in the first 3 d after myocardial infarction ( Supplementary Fig. 5 ), arguing against an antibody-mediated effect. The moderate decrease of IgM levels observed at day 14 after myocardial infarction in CD20 mAb-treated mice ( Supplementary  Fig. 5 ) might be secondary to the reduction of myocardial necrosis. We next assessed changes in the inflammatory response. Treatment with CD20 mAb resulted in markedly lower levels of both systemic and local proinflammatory cytokines measured at day 14 after myocardial infarction ( Fig. 1d and Supplementary Fig. 6a,b) . Interleukin-1β (IL-1β; P = 0.04), tumor necrosis factor-α (TNF-α; P = 0.004) and IL-18 (P = 0.041) mRNA levels were significantly lower in infarcted hearts of B cell depleted-mice compared to the control group (Fig. 1d) . In contrast, expression of the anti-inflammatory mediators IL-10 and TGF-β were not significantly affected in the B cell-depleted mice (Fig. 1d) . We observed similar results in spleens and lymph nodes of B cell-depleted mice ( Supplementary Fig. 6a,b) , suggesting a blunted inflammatory response.
B cell depletion alters monocyte compartmentalization
We next sought to address the mechanisms that could account for the reduced inflammatory response and the improvement in ventricular remodeling after CD20 mAb treatment. B cell-depleted mice showed altered monocyte compartmentalization after acute myocardial infarction, as revealed by enhanced accumulation of 7/4 hi monocytes in the bone marrow (P = 0.01 versus PBS-treated controls) (Fig. 2a ) and the spleen (P = 0.02 versus PBS-treated controls) ( Supplementary  Fig. 7 ), associated with a significant decrease of 7/4 hi monocyte circulating blood counts (P = 0.015 versus PBS-treated controls) (Fig. 2b) . These results suggest that B cell depletion impairs monocyte mobilization after acute myocardial infarction.
We also addressed the effect of CD20-mediated B cell depletion on monocyte recruitment from the circulating blood into the ischemic heart. Mice underwent coronary artery ligation and 1 h after ligation were treated with either PBS or CD20 mAb. Four hours after ligation, the two groups of mice received an intravenous infusion of CD45.1 + bone marrow-derived mononuclear cells (15 × 10 6 ) isolated from wild-type (WT) mice, and we quantified the number of recruited CD45.1 + CD11b + Ly6G − Ly6C + cells in the myocardium 3 d after monocyte transfer. CD20-mediated B cell depletion led to a substantial reduction in monocyte recruitment into the ischemic myocardium (Fig. 2c) . We also found a nonsignificant trend toward reduced accumulation of 7/4 hi monocytes 3 d after CD20 mAb treatment ( Supplementary Fig. 8a ) and a substantial reduction of macrophage accumulation within the ischemic heart 5 d after CD20 mAb treatment (Fig. 2d) . Other cell subsets were not altered ( Supplementary Fig. 8b,c) .
B lymphocytes produce Ccl7 and trigger monocyte migration
Given that Ccr2-mediated signals are required for monocyte mobilization from the bone marrow 17, 28 and recruitment into injured tissues, we examined potential changes in the production of Ccl2 and Ccl7, the two major Ccr2 ligands. We found that acute myocardial infarction led to substantial increases of Ccl2 and Ccl7 mRNA and protein levels in blood and cardiac tissue (Supplementary Fig. 9 ). Notably, B cell depletion was associated with a significant and selective impairment npg of Ccl7 protein levels (P = 0.03) compared to the control group, whereas Ccl2 (and Ccl12) levels were not significantly affected by B cell depletion ( Fig. 3a and Supplementary Fig. 9 ).
These results suggest that B lymphocytes might produce Ccl7 to mobilize monocytes. To address this hypothesis, we first evaluated Ccl7 expression by splenic B cells using flow cytometry and reversetranscription quantitative PCR (RT-qPCR). We found that CD19 + B lymphocytes, which are markedly depleted after CD20 mAb treatment, express Ccl7, with higher expression after myocardial infarction (Supplementary Fig. 10 ). Splenic B cells from Myd88 −/− ; Trif −/− mice, which cannot respond to Toll-like receptor (TLR) signaling, produced substantially less Ccl7 than did splenic B cells from WT mice at day 1 after myocardial infarction (Supplementary Fig. 10 ), suggesting at least a partial dependence on TLR signaling. We also assessed Ccl7 secretion by cultured splenic B lymphocytes isolated from WT mice. Whereas Ccl2 and Ccl12 were undetectable in the supernatants of B lymphocytes from WT mice (data not shown), these cells produced a substantial amount of Ccl7 that was further increased after their activation with CD40-specific and IgM-specific antibodies (data not shown) or with TLR agonists, particularly CpG ( Fig. 3b and Supplementary  Fig. 10 ). Control oligodeoxynucleotides, which are unable to stimulate TLRs, did not induce Ccl7 production (data not shown). We also found that activated cultured B lymphocytes strongly enhanced 7/4 hi monocyte transmigration in vitro compared to nonstimulated B lymphocytes (P < 0.0001) (Fig. 3c) . Notably, neutralizing antibody to Ccl7 abrogated B cell-induced migration of cultured 7/4 hi monocytes (P = 0.0003), whereas Ccl2 neutralization had no effect (Fig. 3c) .
Ccl7-deficient B cells fail to affect cardiac function
These findings prompted us to investigate the direct role of B cellderived Ccl7 in post-ischemic cardiac remodeling. First, we studied the role of Ccl7 in this setting using Ccl7-deficient mice. We found that after acute myocardial infarction, Ccl7 deficiency was associated with a reduction of 7/4 hi monocyte mobilization from the bone marrow (P = 0.013 versus WT) to the blood (P = 0.04 versus WT) and improvement of cardiac function (Supplementary Fig. 11 ). To further substantiate the role of B cell-derived Ccl7 in this setting, we injected Rag1 −/− mice (lacking B and T cells) with either WT splenocytes, B cell-depleted splenocytes or B cell-depleted splenocytes resupplemented with WT or Ccl7 −/− B lymphocytes. The purity of the B lymphocytes is shown in Supplementary Figure 12 . We first verified that resupplementation with WT or Ccl7 −/− B lymphocytes substantially increased B cell numbers in the spleens of Rag1 −/− mice compared to mice injected with B cell-depleted splenocytes only ( Supplementary  Fig. 12 ). Resupplementation with WT B lymphocytes was associated with higher circulating Ccl7 concentrations compared to mice receiving B cell-depleted splenocytes only (968.5 ± 46.06 pg ml −1 and 201.1 ± 28.31 pg ml −1 , respectively, P < 0.0001). In contrast, resupplementation of B cell-depleted splenocytes with B lymphocytes isolated from Ccl7 −/− mice failed to increase Ccl7 concentrations (152.6 ± 39.9 pg ml −1 , P < 0.0001 versus WT B lymphocytes). We also found that resupplementation with WT B lymphocytes was associated with higher 7/4 hi monocyte numbers in the blood and within the injured myocardium compared to the group receiving B cell-depleted splenocytes only (Fig. 3d) , an effect that was abrogated in mice resupplemented with Ccl7 −/− B lymphocytes (Fig. 3d) . Thus, B cell-derived Ccl7 triggers selective mobilization and tissue recruitment of 7/4 hi monocytes after acute myocardial infarction.
We next examined the consequences of Ccl7 deficiency in B lymphocytes on post-ischemic cardiac remodeling. We found that transfer of B cell-depleted splenocytes into Rag1 −/− mice reduced end-systolic left ventricular chamber dimension (P = 0.04) and improved left ventricular fractional shortening (P = 0.008) after myocardial infarction compared to transfer of nondepleted splenocytes (Fig. 4a) . This effect was abrogated after resupplementation of B cell-depleted splenocytes with B lymphocytes isolated from WT mice (P = 0.0007 and P = 0.02, respectively) but was not altered after resupplementation with Ccl7 −/− B lymphocytes (Fig. 4a) . B cell depletion also reduced infarct size (P = 0.04; Fig. 4b ) and collagen content (Fig. 4c) ; these effects were blunted by resupplementation with WT but not with Ccl7 −/− B lymphocytes (Fig. 4b,c) . Circulating IgM and IgG concentrations were similar in mice resupplemented with WT versus Ccl7 −/− B lymphocytes ( Supplementary Fig. 12 ), making a contribution of humoral immunity to the cardioprotective effect unlikely, although we did not measure specific antibody titers. We also generated a B cell-restricted Ccl7-deficient mouse model by reconstituting lethally irradiated WT mice with a mixture of bone marrow from µMT (B cell-deficient) and Ccl7 −/− mice (see Online Methods). The control group received a mixture of µMT and Ccl7 +/+ bone marrow. Again, we found that restricted Ccl7 deficiency in B lymphocytes led to a reduction of circulating Ccl7 concentrations (Fig. 4d) and improved heart function after acute myocardial infarction (Fig. 4e) .
Role of Baff signaling in post-ischemic myocardial injury
Baff signaling through Baff receptor (Baff-r, encoded by Tnfrsf13c) is required for the maintenance of mature B2 cells, and Baff-r deficient (Tnfrsf13c −/− ) mice are characterized by a profound reduction of follicular and marginal zone B lymphocytes but preservation of B1 cells 29 (Supplementary Fig. 13 ). We therefore addressed the impact of Baff-r deficiency on the pathophysiology of post-ischemic myocardial injury. We found that Tnfrsf13c −/− mice showed significantly more accumulation of Ly6C hi monocytes in the bone marrow but had lower numbers of these monocytes in the circulating blood compared with control littermates (Fig. 5a and Supplementary  Fig. 13 ), suggesting that these mice have impaired monocyte mobilization. Tnfrsf13c −/− mice also had lower concentrations of circulating Ccl7 compared to control mice (Fig. 5b) . Notably, Baff-r deficiency improved heart function after myocardial infarction, as shown by a (Fig. 5c) , despite having no effect on infarct size (Supplementary Fig. 13 ). To further substantiate the role of Baff in this context, we treated a group of WT mice with a Baffspecific monoclonal antibody (Online Methods). We found that Baff neutralization led to significant depletion of circulating B lymphocytes (Fig. 5d) , which was associated with impaired Ly6C hi monocyte mobilization ( Fig. 5e and Supplementary Fig. 13 ) and improved cardiac function (Fig. 5f ).
Blood levels of CCL7 and BAFF and cardiovascular outcome Finally, we addressed the relevance of these findings to the human disease by assessing the relationship between circulating CCL7 or BAFF concentrations and clinical outcomes in a cohort of 1,000 patients admitted for acute myocardial infarction. The patients' characteristics are given in Supplementary Tables 1 and 2. We found that patients with detectable circulating concentrations of CCL7 at the time of admission were at substantially higher risk of death and recurrent myocardial infarction after 2 years of follow-up compared to patients with no detectable CCL7, even after adjustment for several multivariable risk factors (see Online Methods) (hazard ratio = 1.54, 95% confidence interval = 1.07-2.43, P = 0.02) (Fig. 6a) . Similarly, the risk of death and recurrent myocardial infarction was associated with increasing tertiles of circulating BAFF concentrations at admission. The hazard ratio of death and recurrent myocardial infarction in the second and third tertiles of BAFF were 1.65 (1.05-2.58) and 3.14 (2.09-4.73), respectively, compared with the lowest tertile (P < 0.0001). The association remained significant in a fully adjusted model (Fig. 6b) .
DISCUSSION
B lymphocytes have crucial nonredundant roles mediating both innate and adaptive immune responses through both antibodydependent and antibody-independent mechanisms. Recent studies have identified new roles for B lymphocytes in the early innate immune response during acute infection 30, 31 , where B lymphocytes were required to mount an efficient and protective inflammatory response. However, the contribution of B lymphocytes to the inflammatory response secondary to other forms of acute injury, particularly post-ischemic injury, is still poorly defined. Our results uncover a key role for B cell-dependent Ccl7 production in the pathogenic response to acute ischemic injury. The precise B cell subset involved in this setting remains to be examined in more detail. However, our results indicate that this pathogenic effect of B cells depends in part on Baff-r signaling. Previous studies did not find a role for B cell responses in post-ischemic stroke injury, as µMT mice showed no difference in infarct size or neurological deficit when compared with WT mice 32 . Other studies addressed the role of B lymphocytes in response to ischemia-reperfusion injury in the kidney. However, very divergent results have been obtained by different groups using B cell-deficient µMT mice in this setting, with studies showing either protection 33, 34 or aggravation 12 of ischemia-reperfusion injury. Effects seen in µMT mice should be interpreted with caution given the wide range of immune abnormalities in these mice, as both innate and adaptive B lymphocytes, with potentially divergent functions, are absent. A previous study showed that intramyocardial injection of bone marrow-derived B cells after acute myocardial infarction in rats improves the recovery of myocardial function 35 . However, there are major differences between that study and our current work. In the previous study, the injected bone marrow-derived B lymphocytes were mostly immature B cells, which are known to be resistant to CD20 mAb-mediated B cell depletion. In addition, the mechanisms of protection afforded by immature B lymphocyte injection were unclear, and the investigators did not assess the role of endogenous B lymphocytes.
We and others have shown that Baff-r deficiency or CD20 mAbinduced B cell depletion holds promise in the context of cardiovascular disease and reduces the development of atherosclerotic lesions in several experimental models 25, [36] [37] [38] . Our present data show that depletion of mature B lymphocytes after CD20 mAb injection during the acute phase of myocardial infarction leads to marked improvement in both post-ischemic ventricular remodeling and myocardial function. We obtained similar results with Baff-r deficient mice or a neutralizing Baff-specific antibody. CD20 mAb treatment also led to a substantial reduction of infarct size, which was not observed after blockade of Baff signaling. It should be noted that Baff-r is also expressed on non-B cells and may activate multiple cell types with opposite and confounding effects on cardiac homeostasis. In addition, B cell depletion in mice treated with Baff-specific antibody was delayed, so that a second antibody injection at day 1 was necessary to obtain a substantial depletion. In contrast, B cells quickly disappeared from the blood in CD20 mAb-treated mice after a single antibody injection.
Future work should address the mechanisms responsible for B cell activation after acute ischemic injury and the pathways that drive B celldependent Ccl7 production. For example, endogenous Toll-like receptor ligands might accumulate after necrosis and could lead to B cell activation. Notably, splenic B cells of Myd88 −/− ; Trif −/− mice, which are unable to respond to TLR stimulation, produced substantially less Ccl7 than did splenic B cells of WT mice. Whether this effect is related to selective Myd88 or Trif (or both Myd88 and Trif) signaling in B cells and whether this effect can directly affect systemic Ccl7 concentrations remains to be determined. Moreover, it will be important to address in more detail the contribution of the various B cell and monocyte subsets to post-ischemic injury. The substantial reduction of the number of Ly6C lo monocytes in blood after B cell depletion or blockade of Baff signaling might be in part related to reduced Ccl7 signaling 28 or may suggest the involvement of additional chemokine pathways, such as the Cx3cr1 pathway. However, we found no difference in Cx3cl1 production between CD20-depleted and control mice (unpublished results, Y.Z.). Finally, pilot data suggest that Cxcl13 may be induced after myocardial infarction (unpublished results, Y.Z.) and might therefore have a role in B cell recruitment into the ischemic heart. In summary, these studies delineate a key contributory role for systemic B cells during the immune responses that lead to tissue damage after acute myocardial infarction. Neutrophils, monocyte subsets, NK cells and T cells enter the site of injury. The release of inflammatory mediators and tissue antigens seems to result in the rapid activation of B cells systemically, which leads to B cell production of Ccl7, in part through a Myd88 and/or Trif-dependent pathway. B cells are also secondarily recruited to the ischemic heart as a component of the inflammatory response. B cell-derived Ccl7 probably acts synergistically with Ccl7 produced from other cellular sources to increase serum chemokine concentrations, facilitating the mobilization of monocytes from the bone marrow and resulting in enhanced monocyte entry into sites of tissue damage. B cell depletion reduces Ccl7 production and the magnitude of 7/4 hi monocyte recruitment and macrophage accumulation into post-ischemic tissues. Because B cells are well known to promote proinflammatory innate and adaptive immune responses 39 , their systemic depletion is likely to further reduce T cell-, macrophage-and neutrophil-induced tissue damage by reducing the systemic amplification of the inflammatory response after myocardial infarction. As a consequence, B cell depletion has a profound impact on post-ischemic injury, as shown here. B cell depletion substantially limits myocardial inflammation, reduces infarct size and improves myocardial function. The positive association of circulating concentrations of BAFF and CCL7 with adverse outcomes in patients with acute myocardial infarction strongly supports the clinical relevance of these findings to the human disease.
In our experiments, CD20 mAb and Baff-specific mAb were administered 1 h after the induction of myocardial infarction, mimicking the clinical setting in which a therapeutic agent is administered in the first hours after the onset of clinical signs of acute ischemic injury. Thus, we believe that our study sets the stage for the testing of available humanized B cell-depleting antibodies during the acute phase of myocardial infarction with the aim of limiting myocardial necrosis and inflammation and improving the recovery of heart function. In addition, we anticipate that therapies targeting pathways that control mature B lymphocytes, such as Baff and Ccl7 pathways, should be of interest in the setting of acute ischemic injury.
METHODS
Methods and any associated references are available in the online version of the paper. 
